Tabone-Eglinger S - Search Results

1

Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P. Arifi S, et al. Bull Cancer. 2008 Jan;95(1):99-106. doi: 10.1684/bdc.2008.0557. Bull Cancer. 2008. PMID: 18230575 Review. French.

2

KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors.

Tabone-Eglinger S, Subra F, El Sayadi H, Alberti L, Tabone E, Michot JP, Théou-Anton N, Lemoine A, Blay JY, Emile JF. Tabone-Eglinger S, et al. Clin Cancer Res. 2008 Apr 15;14(8):2285-94. doi: 10.1158/1078-0432.CCR-07-4102. Clin Cancer Res. 2008. PMID: 18413817 Free article.

3

Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas.

el Sayadi H, Pissaloux D, Alberti L, Tabone-Eglinger S, Ranchere D, Decouvelaere AV, Tabone E, Ray-Coquard I, Caux C, Fayette J, Blay JY. el Sayadi H, et al. Target Oncol. 2013 Dec;8(4):261-9. doi: 10.1007/s11523-012-0249-2. Epub 2013 Jan 25. Target Oncol. 2013. PMID: 23354874

4

Gene expression patterns of hemizygous and heterozygous KIT mutations suggest distinct oncogenic pathways: a study in NIH3T3 cell lines and GIST samples.

Bachet JB, Tabone-Eglinger S, Dessaux S, Besse A, Brahimi-Adouane S, Emile JF, Blay JY, Alberti L. Bachet JB, et al. PLoS One. 2013 Apr 12;8(4):e61103. doi: 10.1371/journal.pone.0061103. Print 2013. PLoS One. 2013. PMID: 23593401 Free PMC article.

5

Effects of endoplasmic reticulum stressors on maturation and signaling of hemizygous and heterozygous wild-type and mutant forms of KIT.

Brahimi-Adouane S, Bachet JB, Tabone-Eglinger S, Subra F, Capron C, Blay JY, Emile JF. Brahimi-Adouane S, et al. Mol Oncol. 2013 Jun;7(3):323-33. doi: 10.1016/j.molonc.2012.10.008. Epub 2012 Oct 30. Mol Oncol. 2013. PMID: 23146721 Free PMC article.

6

Prognosis and predictive value of KIT exon 11 deletion in GISTs.

Bachet JB, Hostein I, Le Cesne A, Brahimi S, Beauchet A, Tabone-Eglinger S, Subra F, Bui B, Duffaud F, Terrier P, Coindre JM, Blay JY, Emile JF. Bachet JB, et al. Br J Cancer. 2009 Jul 7;101(1):7-11. doi: 10.1038/sj.bjc.6605117. Epub 2009 Jun 16. Br J Cancer. 2009. PMID: 19536093 Free PMC article.

7

Niche anchorage and signaling through membrane-bound Kit-ligand/c-kit receptor are kinase independent and imatinib insensitive.

Tabone-Eglinger S, Calderin-Sollet Z, Pinon P, Aebischer N, Wehrle-Haller M, Jacquier MC, Boettiger D, Wehrle-Haller B. Tabone-Eglinger S, et al. FASEB J. 2014 Oct;28(10):4441-56. doi: 10.1096/fj.14-249425. Epub 2014 Jul 7. FASEB J. 2014. PMID: 25002122

8

GIST with homozygous KIT exon 11 mutations.

Emile JF, Bachet JB, Tabone-Eglinger S, Terrier P, Vignault JM. Emile JF, et al. Lab Invest. 2008 May;88(5):456-7. doi: 10.1038/labinvest.2008.13. Lab Invest. 2008. PMID: 18432212 Free article. No abstract available.

9

Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.

Tabone-Eglinger S, Bahleda R, Côté JF, Terrier P, Vidaud D, Cayre A, Beauchet A, Théou-Anton N, Terrier-Lacombe MJ, Lemoine A, Penault-Llorca F, Le Cesne A, Emile JF. Tabone-Eglinger S, et al. Sarcoma. 2008;2008:849156. doi: 10.1155/2008/849156. Sarcoma. 2008. PMID: 18769552 Free PMC article.

10

Prognostic value of KIT exon 11 deletions in GISTs.

Emile JF, Tabone-Eglinger S, Théou-Anton N, Lemoine A. Emile JF, et al. Gastroenterology. 2006 Sep;131(3):976-7; author reply 977-8. doi: 10.1053/j.gastro.2006.07.042. Gastroenterology. 2006. PMID: 16952576 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters